MedPath
HSA Approval

EZETIMIBE MEVON TABLET 10 MG

SIN16441P

EZETIMIBE MEVON TABLET 10 MG

EZETIMIBE MEVON TABLET 10 MG

March 8, 2022

NOVEM PHARMA PRIVATE LIMITED

NOVEM PHARMA PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVEM PHARMA PRIVATE LIMITED
Licence HolderNOVEM PHARMA PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

**4.2. Posology and method of administration** Posology The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with Ezetimibe MEVON. The recommended dose is one Ezetimibe MEVON 10 mg tablet daily. When Ezetimibe MEVON is added to a statin, either the indicated usual initial dose of that particular statin or the already established higher statin dose should be continued. In this setting, the dosage instructions for that particular statin should be consulted. _Co-administration with bile acid sequestrants_ Dosing of Ezetimibe MEVON should occur either ≥ 2 hours before or ≥ 4 hours after administration of a bile acid sequestrant. _Elderly_ No dosage adjustment is required for elderly patients (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Paediatric population_ Initiation of treatment must be performed under review of a specialist. Children and adolescents ≥ 10 years: No dosage adjustment is required. Children < 10 years: Treatment with ezetimibe is not recommended. _Hepatic impairment_ No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6). Treatment with Ezetimibe MEVON is not recommended in patients with moderate (Child-Pugh score 7 to 9) or severe (Child-Pugh score > 9) liver dysfunction (see sections 4.4 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Renal impairment_ Monotherapy In patients with renal impairment, no dosage adjustment of ezetimibe is necessary (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Combination therapy with simvastatin In patients with mild renal impairment (estimated GFR ≥60 mL/min/1.73 m2), no dosage adjustment of ezetimibe or simvastatin is necessary. In patients with chronic kidney disease and estimated glomerular filtration rate <60 mL/min/1.73m2, the dose of ezetimibe is 10 mg and the dose of simvastatin is 20 mg once a day in the evening. In such patients, the use of higher doses of simvastatin should be closely monitored. Method of administration Route of administration is oral. Ezetimibe MEVON can be administered at any time of the day, with or without food.

ORAL

Medical Information

**4.1. Therapeutic indications** Primary Hypercholesterolaemia Ezetimibe MEVON co-administered with an HMG-CoA reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia. Homozygous Familial Hypercholesterolaemia (HoFH) Ezetimibe MEVON co-administered with atorvastatin or simvastatin, is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. Homozygous Sitosterolaemia (Phytosterolaemia) Ezetimibe MEVON is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.

**4.3. Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. When Ezetimibe MEVON is co-administered with a statin, please refer to the SmPC for that particular medicinal product. Therapy with Ezetimibe MEVON co-administered with a statin is contraindicated during pregnancy and lactation. Ezetimibe MEVON co-administered with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.

C10AX09

ezetimibe

Manufacturer Information

NOVEM PHARMA PRIVATE LIMITED

Atlantic Pharma – Produções Farmacêuticas, S.A.

Active Ingredients

Ezetimibe

10 mg

Ezetimibe

Documents

Package Inserts

Ezetimibe Mevon Tablet PI.pdf

Approved: March 8, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.